Brought to you by 
Series A brings $20mm to Exosome Diagnostics
18 Sep 2020
Executive Summary
Cancer testing start-up Exosome Diagnostics Inc. (ED) raised $20mm through its Series A round co-led by NGN Capital and Forbion Capital Partners, which each also contribute members to Exosome's board.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings $20mm to Exosome Diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice